---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-022060"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T08:07:27.195925+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools FY2023 revenue $106M (+9%); Q4 gross margin 59.6%; SomaLogic merger closed

## Summary
- FY2023 revenue $106.3M (+9% YoY); Q4 revenue $28.2M (+4%); instrument sales +46% for FY.
- Non-GAAP gross margin 60.1% for FY2023 (+900 bps YoY); net loss $74.7M.
- Non-GAAP adjusted EBITDA loss improved $34M to $34.7M; operating cash use down 53%.
- Combined pro forma 2023 revenue ~$192M; pro forma cash $565M (incl. SomaLogic's $449.8M).
- Merger with SomaLogic closed Jan 5, 2024; integration underway; CEO cites disciplined execution.

## SEC filing metadata
- accession: 0000950170-24-022060
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000095017024022060/0000950170-24-022060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000095017024022060/lab-20240228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-022060
- JSON: https://secwatch.observer/filing/0000950170-24-022060.json
- Plain text: https://secwatch.observer/filing/0000950170-24-022060.txt

## Key facts
- Earnings Releases
  STANDARD BIOTOOLS INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $28.2, net income $(19.8).
  - Period: the fourth quarter and fiscal year ended December 31, 2023
  - Revenue: $28.2
  - Net income: $(19.8)
  - Result: reported results
  source text: 2023 Fourth Quarter and Full Year Selected Financial Results 2 Quarter Ended Year Ended (Unaudited, in millions, except percentages) December 31, 2023 December 31, 2023 Revenue $ 28.2 $ 106.3 GAAP gross margin 47.4 % 47.4 % Non-GAAP gross margin 59.6 % 60.1 % Operating expenses $ 34.7 $ 127.1 Non-GAAP operating expenses $ 24.3 $ 98.6 Operating loss $ (21.4 ) $
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000095017024022060/0000950170-24-022060-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.